Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Aarcoron Nov 24, 2020 4:32pm
172 Views
Post# 31963274

RE:RE:Anybody else around here...

RE:RE:Anybody else around here...Looking forward to some hopium!  Notwithstanding our quarterly option grant news or patent approvals, shareholders are getting restless for something/anything to happen.  The lone deal in the last year is getting a little stale and so we are still some ways from 18 & 4.  Stale also is the latest corporate presentation that indicates xb3-001 phase1 is now pushed out into 2022.  Denali is so far out in front that we can't even see their dust any longer.  Doesn't matter because if you get real close our mice will tell you that xb3 really works!

Bioasis has understanding shareholders.  The best.  We have some real experts here that have pointed out for almost a decade or thereabouts that "things always take longer than people expect".  This of course has been proven 100% true, especially so when the business plan is to hope for other potential partners to figure out a solution for you.   

So, we're in desperate need of another hopium injection right before the AGM, which, by the way, should provide everyone an opportunity for an hour long uninterrupted nap.  Then its holiday time, and we'll all be happy thinking about what great things will happen in 2021.  Just like we did for 2016 and 2017 and 2018 and 2019 and 2020.

So let's be positive because we all know that if we question management's plan and execution, we're hurting our investment.  So go get em Dr Rathjen!.  Can't wait for 2021!
<< Previous
Bullboard Posts
Next >>